The link between ERG rearrangement and PTEN (phosphatase and tensin homolog deleted on chromosome 10) deletion is unclear in prostate cancer progression. Using fluorescence in situ hybridization, we systematically validated the frequency and distribution of ERG and PTEN aberrations in a cohort of 73 benign prostate tissues, 59 high-grade prostatic intraepithelial neoplasia (HGPIN) foci, 281 localized prostate cancer and 47 androgenindependent metastatic prostate cancer patients. Overall, ERG rearrangement was present in 15% (5/33) of HGPIN, 45% (121/267) of localized cancers and 35% (15/43) of metastases. By contrast, PTEN deletion was identified in 9% (3/33) of HGPIN, 17% (42/251) of localized cancers and 54% (22/41) of metastases, of which 0%, 40% (17/42) and 45% (10/22) were homozygous, respectively. Concomitance of ERG rearrangement and PTEN deletion was observed in a subset of HGPIN. Significantly, association between PTEN deletion and ERG rearrangement was present both in localized cancers (P ¼ 0.0008) and metastases (P ¼ 0.02). Further, immunohistochemistry revealed significant correlation of decreased PTEN protein expression with PTEN genomic deletion both in localized and metastatic cancer. Of note, ERG aberration, but not PTEN deletion, was consistently identical both in localized cancer and adjacent HGPIN. Similarly, whereas all metastases (41/41, 100%) shared the same ERG status across multiple sites from the same patient, 5% (2/41) of cases showed discordance for PTEN deletion status across multiple sites. Collectively, our data support PTEN deletion as a late genetic event in human prostate cancer, presumably a 'second hit' after ERG rearrangement. PTEN deletion and ERG rearrangement may cooperate, but contribute at different stages, in prostate cancer progression. Modern Pathology ( It proceeds through a putative precursor lesion, termed high-grade prostatic intraepithelial neoplasia (HGPIN), to hormone naive clinically localized cancer and finally to androgen-independent metastatic cancer.
metastatic cancers. [10] [11] [12] As TMPRSS2 and ERG are located B3 Mb apart on chromosome 21, the rearrangement between them occurs either through translocation or by an interstitial deletion. 13 Emerging data suggest that TMPRSS2-ERG fusion plays an important role in carcinogenesis in vitro and in vivo. 14, 15 Clinically, ERG rearrangement has been observed in 10B20% of HGPIN. [16] [17] [18] Mosquera et al 18 showed that of 143 HGPIN cases, 16% (23 of 143) were ERG rearrangement positive, and in all cases the paired prostate cancer was ERG rearrangement positive through the same mechanism. These observations suggest that ERG rearrangement may be an early event in prostate cancer. Additionally, studies in watchful waiting cohorts suggest that ETS rearrangement cancers is associated with a more aggressive phenotype; however, conflicting reports have been described in prostatectomy series. 12, [19] [20] [21] [22] PTEN (phosphatase and tensin homolog deleted on chromosome 10) is a key tumor suppressor gene in prostate cancer. 23 Loss of PTEN function results in increased PIP3 (Phosphatidylinositol (3,4,5)-triphosphate) levels and subsequent AKT phosphorylation and modulation of its downstream molecular oncogenic processes. 24 A series of in vivo studies have shown the role of PTEN in prostate carcinogenesis with prostate-specific deletion. 25, 26 Clinically, deletion or mutation of at least one PTEN allele was reported to occur in 20-40% of localized cancers [27] [28] [29] and up to 60% of metastases. 30 Fluorescent in situ hybridization (FISH) and immunohistochemical studies showed that PTEN genomic deletion and absence of PTEN expression are associated with unfavorable clinical outcome measures. [29] [30] [31] Recent studies also showed that PTEN inactivation plays an important role in prostate cancer during progression to androgen-independence. 32, 33 Whereas ERG rearrangement and PTEN deletion are strongly implicated in prostate cancer development, little is known about the link between these two genomic events. Most recently, Yoshimoto et al 34 reported that TMPRSS2-ERG fusion could be accompanied by PTEN deletion in localized prostate cancer. However, there has been no systematic FISH validation on these genomic aberrations in the context of prostate cancer progression. Hence, we comprehensively evaluated a wide spectrum of benign tissues, premalignant and malignant lesions to characterize ERG rearrangement and PTEN deletion during prostate cancer progression.
Materials and methods

Study Population, Clinical Data and Tissue Microarray (TMA)
A total of six TMAs were interrogated in this study that represents: (1) 
Case Selection for HGPIN
A total of 59 HGPIN present in prostatectomy specimens from 56 localized prostate cancers represented in this cohort were also included in the study. Initially, we randomly chose 34 HGPIN lesions from equal number of localized cancer patients to assess the frequency of PTEN deletion and/or ERG rearrangement. We further reviewed localized cancer patients that harbored known ERG and/or PTEN genomic aberrations and selected 20 cases containing HGPIN to analyze association of PTEN and ERG aberrations. All HGPIN lesions were selected by three pathologists (BH, RM and RBS) by consensus and divided into two categories: those adjacent to cancer (distance o3 mm from the edge of the cancer, HGPINadj) or those away from cancer (distance 43 mm from the closest cancer in any single section and 4 mm from the closest cancer on the adjacent section above or below, HGPINaway). 35 Although HGPINadj cases selected for the study may potentially represent an intraductal spread of prostate cancer, none of the HGPINadj lesions included in the study morphologically contained high-grade pleomorphic nuclei, which are 6 Â size of normal nuclei and/or intraluminal comedonecrosis, features usually considered characteristic of an intraductal spread of cancer. 36 Fluorescence In Situ Hybridization
Interphase FISH was carried out as described. 8, 11 Bacterial artificial chromosomes (BACs) were obtained from the BACPAC Resource Center (Oakland, CA, USA), and probes were prepared as described. 3, 11 For detection of ERG rearrangement, RP11-95I21 (5 0 to ERG) and RP11-476D17 (3 0 to ERG) were used with a break-apart probe strategy. 11 To detect PTEN deletion, a combination of PTEN gene locus-specific probe (RP11-165M8) and 10q11.1-specific probe (RP11-351D16) for chromosome identification were utilized. Schematic BACs for ERG and PTEN are shown in Figure 1a . The integrity and correct localization of all probes were verified by hybridization to metaphase spreads of normal peripheral lymphocytes. Slides were examined using an ImagingZ1 microscope (Carl Zeiss, Oberkochen, Germany). FISH signals were scored manually ( Â 100 oil immersion) in morphologically intact and non-overlapping nuclei by two pathologists (BH and RM), and a minimum of 50 cancer cells from each site were recorded. Cancer sites with very weak or no signals were recorded as insufficiently hybridized. Cases lacking tumor tissue in all three cores were excluded.
For validation of PTEN deletion, we utilized an earlier documented method with minor modification. 37 Briefly, on the basis of hybridization in five control cores (data not shown), hemizygous deletion of PTEN gene was defined as 450% nuclei (mean±3 standard deviations in nonneoplastic controls) containing either one signal of locus probe and Z2 signals of reference probe (absolute deletion), or two signals of locus probe and Z4 signals of reference probe (relative deletion). Homozygous deletion of PTEN was exhibited by the simultaneous lack of the both PTEN locus signals and the presence of control signals in 430% of cells. 29, 34, 37 Representative FISH images of PTEN deletion and ERG rearrangement are shown in Figure 1b . 
Immunohistochemistry (IHC)
Immunohistochemistry was carried out using a rabbit polyclonal antibody against PTEN (Ab9552, Cell Signaling, MA, USA) on TMA using 1:100 dilution, and incubated overnight at 41C following standard LSAB immunohistochemical staining protocol. 38 The slides were evaluated blindly by three independent observers (BH, KS and RM). Triplicate cores from each specimen were scored separately, and the presence of tumor tissue in at least two interpretable cores was required to include a case for analysis. According to the cytoplasmic staining intensity, the tumors were divided into three categories as described earlier:
39,40 grade 2 showed increased or equal staining intensity compared with the corresponding normal tissue; grade 1 had decreased staining intensity and grade 0 showed complete absence of staining.
Statistical Analysis
Fisher's exact test was used to test the statistical significance of associations between PTEN deletion status and ERG rearrangement status, as well as the association between PTEN genomic deletion status and PTEN protein expression level, with P-values o0.05 being considered statistically significant. Statistical analyses were carried out using the R software package, version 2.7.2 (http://www. r-project.org).
Results
Frequency of PTEN Deletion and ERG Rearrangement
To determine the frequency of PTEN and ERG genomic aberrations in different prostate tissue types, we screened a wide spectrum of prostate lesions and benign prostate tissues represented on multiple TMAs. As shown in Table 1 , PTEN deletion was found in 17% (42/251) of the localized prostate cancer patients, out of which 60% (25/42) exhibited hemizygous deletion. In androgen-independent metastatic prostate cancer, PTEN deletion was present in 54% (22/41) of cases, among which 55% (12/22) showed hemizygous deletion. By contrast, only 9% (3/33) of HGPIN showed PTEN deletion, all of which were hemizygous.
Overall, ERG was rearranged in 45% (121/267) of the localized prostate cancer cases, of which 55% (67/121) showed deletion of the 5 0 end of ERG (Table 1) . A similar frequency of ERG rearrangement (35%, 15/43) was observed in androgen-independent metastatic cancers as reported earlier, 12 the majority showing deletion of the 5 0 end of ERG. By contrast, ERG aberrations were identified in 15% (5/33) of HGPIN, and as expected, were not detected at all in non-neoplastic prostate tissues. Of note, part of our FISH data of ERG aberrations represented on three TMAs have been published before as part of the University of Michigan cohort. 9, 11, 12 Association of PTEN Deletion and ERG Rearrangement in Localized and AndrogenIndependent Metastatic Prostate Cancer
As ERG rearrangement and PTEN deletion are among the most common genomic aberrations in prostate cancer, 10, 23 we next explored the association of these two genomic events in this cohort. As shown in Table 2 , the ERG rearrangement was present in approximately 71% (29/41) of localized cancers with PTEN deletion (hemizygous or homozygous). Likewise, PTEN deletion occurred more frequently in cases that harbored ERG rearrangement (26%, 29/110) as compared with those ERG rearrangement negative cases (9%, 12/127). Of the androgen-independent metastases, co-existence of the PTEN deletion and ERG rearrangement was present in 28% (11/39) of cases. Overall, a significant association between PTEN deletion and ERG rearrangement was observed both in localized prostate cancer (P ¼ 0.0008) and androgen-independent metastatic prostate cancer (P ¼ 0.02) ( Table 2) . Interestingly, for localized cancers with PTEN deletion, ERG fusion-positive cases were more likely to show homozygous deletion of PTEN, although this association did not reach statistical significance (P ¼ 0.08). It is to be noted that there was a total of 
PTEN Deletion and ERG Rearrangement in HGPIN
High-grade prostatic intraepithelial neoplasia is a putative precancerous lesion, and earlier studies have shown that PTEN genomic deletion as well as ERG rearrangement could occur in subset of HGPIN. [16] [17] [18] 41 Additionally, Perner et al 16 showed that ERG rearrangement displayed a different picture in HGPINadj vs HGPINaway. However, it is unclear whether the PTEN deletion and ERG rearrangement could co-exist in HGPIN and what their association is to cancer. To address this, we analyzed 25 HGPIN on prostatectomy specimens from 20 selected localized cancers, which harbored genomic aberrations of ERG and/or PTEN. As shown in Figure 2a ,100% (11/11) HGPINadj shared the same ERG aberrations with the paired cancer foci (T1-T9, T13, T20), which is comparable with earlier studies. 16, 18 By contrast, 60% (6/10) HGPINadj shared the same PTEN genomic aberrations with the paired cancer foci (T7-T11, T13), whereas the remaining four cases were not (T6, T12, T19-20). Of note, concomitance of PTEN deletion and ERG rearrangement were observed in HGPINadj intermingling with cancer foci from four localized cancer patients (T7-T9, T13). Interestingly, no PTEN deletion or ERG rearrangement was observed in HGPINaway. Figure 2b represents a reconstructed map of the prostatectomy sections in index cases T6 and T9. In total, these findings suggest co-existence of ERG rearrangement and PTEN deletion in a subset of HGPINadj.
Homogeneity of ERG Rearrangement, but not PTEN Deletion in Multiple Metastatic Sites of AndrogenIndependent Prostate Cancer
Earlier, we validated TMPRSS2-ETS aberrations in 30 androgen-independent metastatic prostate cancer patients. In patients exhibiting ERG aberrations, we observed that multiple metastatic sites from an individual case harbored the same TMPRSS2-ERG rearrangement, all of which occurred through intrachromosomal deletion. 12 In this study, we extrapolated our initial findings to 47 metastatic prostate cancer patients representing the University of Michigan warm autopsy cohort and evaluated ERG status in 156 tumor foci from different organs as well as the prostate (when present). Similar to our earlier study, 12 ERG was rearranged in 35% (15/43) of cases, and cases were rearranged through deletion of 5 0 end of ERG, except M39, in which ERG split (translocation) was observed (Figure 3a) . Notably, homogeneous ERG aberrations were present in all metastatic sites and primary tumors (when present) within an individual patient. These results support the concept that ERG rearrangement occurs at the clinically localized stage before progression to an androgen-independent metastatic stage in prostate cancer.
We further analyzed PTEN deletion status across all metastatic sites in these 47 cases. As shown in Figure 3b , of 41 interpretable warm autopsy cases, 39 showed concordant PTEN deletion status across all metastatic sites and primary tumors in prostate (when present). By contrast, in two cases (M1 and M5), hemizygous PTEN deletion was identified in metastatic foci of soft tissue (M1) or the liver (M5), but no deletion was present in the prostate and other metastatic sites. We further examined all available paraffin tissue specimens for all the metastatic sites and primary tumors, but did not find any additional cancer foci harboring PTEN deletion in these two cases (data not shown). Thus, these results suggested that PTEN deletion could occur after dissemination of tumor in a small subset of androgen-independent metastatic cancer patients.
Comparison of PTEN Genomic Deletion and PTEN Protein Expression by IHC
We earlier reported that 495% of prostate cancer cases with ERG overexpression harbor TMPRSS2-ERG gene fusions. 3 By contrast, multiple mechanisms account for loss of PTEN protein expression, including genomic deletion, mutation and promoter 23 To explore the association of PTEN gene status with PTEN protein expression, we analyzed 207 prostate cancer patients in this cohort. Predominantly cytoplasmic, with occasional nuclear, staining of PTEN was observed by IHC ( Figure 4a ). As shown in Table 3 , statistically significant associations were observed between PTEN deletion and decreased PTEN protein expression in both localized (Po0.0001) and metastatic (P ¼ 0.045) cancer. Of note, 26 (19%) localized cancer cases revealed decreased PTEN protein expression, but were negative for PTEN genomic deletion, suggesting that reduced PTEN expression might be because of other mechanisms. Additionally, we detected PTEN protein expression in selected HGPINadj with known PTEN genomic aberrations in localized cancer T7-T11 and T13 (Figure 2a) . As expected, all but one (HGPINadj in T9) exhibited decreased or absent PTEN expression.
Concordance between PTEN deletion status and decrease PTEN protein expression was also observed in 28 out of 39 (72%) androgen-independent metastases (Table 3) . Out of 11 discordant cases, decreased (grade 1) or absence (grade 0) of PTEN protein expression was observed in eight cases that were negative for PTEN deletion. In the remaining three cases, normal PTEN protein expression was identified, although PTEN hemizygous deletion was observed.
Discussion
ERG rearrangement and PTEN deletion are two of the most common genomic events in human prostate cancer. In this initial study, we used rearrangements in ERG as a marker for ETS rearrangements in prostate cancer, as 490% of all ETS rearrangements involve ERG. 10 Additionally, as only TMPRSS2 and SLC45A3 have been identified as 5 0 fusion partners of ERG, with SLC45A3-ERG being extremely rare in our PSA-screened radical prostatectomy series, 9 we can conclude that most of the ERG-rearranged prostate cancers are TMPRSS2-ERG fusions (497%). In the current study, for the first time, we have observed significant association of ERG rearrangement and PTEN deletion in clinically localized (n ¼ 281) and androgen-independent metastatic prostate cancers (n ¼ 47). Biologically, we and others have reported that overexpression of ERG resulted in increased cellular invasion in vitro. 14, 15 By contrast, PTEN deletion was associated with a gain of transformation potential and marked increase in cellular proliferation in prostate cancer through its negative regulation of the PI3K pathway. 24 Of note, many studies have shown that PTEN can synergize with other oncogenic factors or related genes in mouse models, including NKx3.1, p27 and p53 to promote cancer development and androgen independence. 25, 42, 43 Although it is unknown whether cross-talk exists between ERG and the PTEN-PI3K pathway, we hypothesize that the interactions between these two genomic aberrations may be synergic or additive. Indeed, while this study was in preparation, Yoshimoto et al 34 reported that concurrent PTEN deletion and TMPRSS2-ERG fusions was present in a subset of prostate cancer cases and associated with an unfavorable outcome. Using Oncomine, they further attempted to explore the potential signaling pathways involved for synergy between these genomic events. How ERG overexpression interacts with PTEN deletion is still unclear and compound transgenic mice recapitulating these lesions will likely be ideal models to further explore this relationship. Using IHC, we also identified significant correlation between decreased PTEN expression and PTEN genomic deletion status, supporting deletion as a major mechanism leading to decreased PTEN protein expression.
Further, we attempted to investigate the roles of ERG and PTEN genomic aberrations in prostate cancer progression. Of note, in line with earlier studies, no benign prostate glands, atrophy or BPH harbored ERG rearrangements. 13, 16 ERG rearrangement was present in B15% of HGPIN lesions in this series. In addition, in 11 selected ERG-rearranged cancer cases, 100% (11/11) HGPIN shared the same ERG rearrangement status with the paired cancer foci, and all of these HGPIN foci were adjacent to the cancer. Although we can not exclude the possibility that HGPINadj lesions may represent an intraepithelial spread from the adjacent invasive cancer or evolved together temporally and developed shared genetic abnormities at the same time, our data, in line with earlier studies, 16 strongly supported ERG aberrations as an early molecular event in prostate cancer development. Earlier, we and other groups have reported that TMPRSS2-ERG gene fusion could induce HGPIN in transgenic mice. 14, 15 It is still not clear whether aberrant ERG overexpression in human induces HGPIN or may drive cancer progression during the transition from HGPIN to localized cancer in human. Further functional characterization, especially using animal models, would be helpful in addressing this issue. By contrast, PTEN deletion was not consistently identical both in localized cancer and adjacent HGPIN. Although a series of in vivo studies have showed that PTEN haploinsufficiency results in the HGPIN in transgenic mouse, 23, 24, 42, 43 in the current study, only 9% (3/33) of human HGPIN lesions harbored PTEN hemizygous deletion. By contrast, we observed a strikingly increase of prevalence for PTEN deletion in androgen-independent metastatic cancer (54%), which is comparable with those reported in recent studies. 31, 33 These findings suggest that PTEN deletion is more likely a late event in prostate cancer progression, although this genetic aberration occurs earlier in tumor evolution in a subset of cases. Further, discordance of PTEN status in different organ sites was observed in a subset of androgenindependent metastatic cancers. That is, PTEN genomic deletion was detected in only one of multiple metastases in cases M1 and M5, but absent in the primary tumor and other organs. This suggests that PTEN deletion occurred during or after the formation of metastatic foci, possibly because of more generalized genomic instability seen in disseminated cancer. Similarly, Suzuki et al 30 has also observed heterogeneity of PTEN genetic aberrations between different metastatic sites within the same patient. Considering the important role of PTEN and high frequency of PTEN aberration in late-stage prostate cancer, one could assume that PTEN deletion may be a critical 'second hit' after ERG rearrangement in a subset of ERG fusion prostate cancer cases. Supporting this concept, by array CGH, Lapointe et al 44 have reported that TMRPSS2-ERG fusions seems to occur before PTEN genomic deletion.
It has been reported that PTEN dose is a key determinant in prostate cancer progression in mouse models. 26 However, our study did not observe a significant difference of PTEN deletion patterns (hemizygous vs homozygous) between localized and metastatic cancers. Therefore, these data suggest that human localized and metastatic prostate cancers do not seem to select for homozygous deletion. Alternatively, hemizygous deletion of PTEN may cooperate with other oncogenic factors including ERG rearrangements during prostate cancer progression, manifesting a phenotype that is equivalent to PTEN homozygous deletion.
Progression to androgen independence is a complex process including clonal selection and adaptation. Recent evidence suggested that PTEN deletion was associated with androgen independence and could functionally control 'two' hits: cell transformation and androgen-independent growth. 32, 33 In the current study, we showed that almost all androgen-independent metastatic cancers harboring ERG rearrangement were associated with the 5 0 deletion of ERG. Thus, we could expect that concomitance of PTEN deletion and ERG rearrangement (through 5 0 end deletion) may select for more aggressive cancers that are able to progress to androgen-independent metastatic cancer. Notably, the co-existence of the PTEN deletion and the ERG rearrangement was present in nearly one-third (11/ 39) of metastatic cases, underscoring the combinatorial roles of aberrant ERG and PTEN in metastatic cancer.
Collectively, our data support PTEN deletion as a late genetic event in human prostate cancer, possibly as a 'second hit' after ERG rearrangement. ERG rearrangement and PTEN deletion may cooperate, but contribute at different stages in prostate cancer progression. Although future work is needed to test this notion, understanding the molecular cross-talk between these two genetic events may provide insight into understanding prostate cancer development. Also, it suggests that simultaneous therapeutic targeting of PTEN and ETS gene fusions may be important for treating a subset of advanced prostate cancers.
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